Insights on Pharmaceuticals & Medical Products

Article

The rise of the next-generation launch room

– Leading pharma companies are using their launch rooms not just to prepare for product launches, but as labs to experiment with design thinking, agile approaches, and advanced analytics.
Article

Rethinking manufacturing and distribution networks in medtech
– Changes in the medtech market have left many companies struggling with their operational footprints. A network redesign can help... them save costs, increase flexibility, and create a competitive edge.
Article

Driving the next wave of innovation in CAR T-cell therapies
– Unlocking the full potential of CAR T-cell therapies requires investment in four areas.
Article

The pursuit of excellence in new-drug development
– Innovations in biomedical sciences and technology fuel the opportunity to transform R&D for new-drug development holistically—500... days faster, better tailored to patient needs, and 25 percent cheaper.
Article

Gene therapy coming of age: Opportunities and challenges to getting ahead
– Amid breakthroughs in gene editing, the pharma industry must recalibrate its development and reimbursement model for therapies... that go beyond the traditional approach to disease treatment.
Article

Bioelectronics ‘jump-start’ the next wave of device therapeutics
– Blurring the lines between pharmaceuticals and medical technology, cybermedicine has the potential to become a pillar of medical... treatment and play a key role in the future of medtech innovation.
Article

Understanding the opportunity in Japan’s biosimilar market
– Despite a sluggish start, Japan’s biosimilar market looks set for accelerated growth. The country’s patient co-pay dynamic, financial... incentives, and commercial model will be keys to success.
Article

Infographic: Europe’s biotech hot spots
– Europe has a complex biotech landscape, with hundreds of companies, multiple paths to innovation and financing, and marked differences... among countries. To see through the complexity, we grouped approximately 1,000 European biotech companies into eight clusters based on country, modality, and therapeutic area. We identified biotech hot spots as well as trends and possible directions for the region. Read more in “Biotech in Europe: A strong foundation for growth and innovation.”

Special Collection

Spotlight on Japan

As the world’s second-largest pharma and medtech market, Japan has historically been an innovation center for the industry. But amid an evolving healthcare landscape, this collection of articles and interviews looks at what opportunities and challenges executives at life-sciences companies need to address.

Want to learn more about how we help clients in Pharmaceuticals & Medical Products?

Learn more

More insights

Article

An engineering approach to derisking R&D for novel drug modalities
– Borrowing from the field of engineering, applying a “failure modes analysis” can quickly take some unnecessary risk... out of a development program for innovative modalities.
Article

Infographic: European biotech financing is maturing, but the gap with the United States keeps growing
– How much financing is needed to encourage growth in Europe’s biotech sector? The analysis in our latest report, “ href="/industries/pharmaceuticals-and-medical-products/our-insights/biotech-in-europe-a-strong-foundation-for-growth-and-innovation">Biotech in Europe: A strong foundation for growth and innovation,” shows that investment in European biotechs is increasing. In late-stage financing, however, Europe lags behind the United States by a large (and still growing) margin—the US sector receives almost five times as much private funding as its European counterpart does. But overall, European biotechs have been good value for investors, and financing is maturing.
Article

Infographic: Building the European biotech sector with world-class talent
– What makes European biotech attractive? Talent is one reason. Europe ranks high in the level of innovation and the quality of... R&D talent, particularly for research, and the amount of available talent in drug development is increasing. For rare diseases and oncology, however, experienced people are considered to be in short supply. And while the challenges of attracting and retaining biotech talent (as well as talent for business development) are not unique to Europe, these will continue to be important for biotech’s growth in this market. Read more in “Biotech in Europe: A strong foundation for growth and innovation.”
Article

Infographic: Europe’s potential for biotech innovation
– Europe has world-class universities, research institutions, medical centers, and hospitals that provide a strong base for sourcing... and developing scientific innovation. However, this strength does not yet translate into patents for new medicines, as Europe trails both China and the United States in that area. Increased investment in biotech may hold the key to helping grow Europe’s share of new drugs. Europe’s biotechs currently receive only 20 percent of the funding their US counterparts do. Read more in “Biotech in Europe: A strong foundation for growth and innovation.”
Article

Biotech in Europe: A strong foundation for growth and innovation
– European companies have an opportunity to play a stronger role in the industry by focusing on three factors.
Article

Unlocking market access for gene therapies in the United States
– Gene therapy holds great promise for treating a variety of diseases, but without changes, today’s payment system could limit... the number of patients who benefit.
Article

The hidden value of improved capital-expenditure management in pharma
– Pharmaceutical companies can reap huge rewards from the hundreds of smaller projects they manage, not just from the occasional... big one. Thinking about value, not just costs, is key.
Article

Designing an agile transformation in pharma R&D
– Pharmaceutical companies are increasingly turning to the concept of agility to help them transform their R&D functions.
Interview

Piloting a biotech leader to greater growth
– Growth in a dynamic biotechnology industry requires empowering teams, making real-time adjustments, and shifting the mind-set... to accelerate toward the end goal.
Report

A vision for medical affairs in 2025
– Four core areas of medical-affairs activity combine to maximize patient experiences and outcomes.
Interview

Agile: The new active ingredient in pharma development
– Roche’s Frank Duff and Malte Schutz explain how trust, a faster pace, and evolutionary design have transformed their highly... technical (and highly regulated) work.
Sorry, we couldn't find any results. Try removing some filters.
View more

Related practice

Connect with our Pharmaceuticals & Medical Products Practice

Contact